Hepatitis E Virus and Immunology Research
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2308
Special Issue Editor
Interests: hepatitis E virus (HEV) tropism; HEV pathogenesis; acute hepatitis; chronic hepatitis; ribavirin; zoonoses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatitis E virus (HEV) was discovered in 1983 using electron microscopy, and the HEV genome was characterized a few years later. Our understanding of the epidemiology and pathophysiology of HEV infection has improved considerably in recent years, but many aspects still remain enigmatic. HEV is the most common cause of acute viral hepatitis worldwide. Improvements in diagnostic algorithms based on serological and molecular tools are associated with a dramatic increase in the number of cases of HEV infection reported to public health authorities. HEV can take different transmission routes depending on the genotype. HEV-1 and HEV-2 are predominant in countries with limited resources, where they are transmitted via contaminated water, while HEV-3 and HEV-4 are predominant in the other countries, where they are transmitted from a large animal reservoir, mainly pigs. HEV-1 can result in fulminant hepatic failure and severe placental disease in pregnant women. We now know that only HEV-3 and HEV-4 can produce chronic hepatitis E in immunocompromised individuals. Furthermore, extra-hepatic manifestations such as neurological and renal manifestations are increasingly being reported. The mechanisms responsible for the variety of clinical manifestations of HEV infection remain poorly characterized. This Special Issue of Vaccines is dedicated to our current knowledge of HEV and future directions of research on HEV vaccines.
Prof. Dr. Jacques Izopet
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HEV
- acute hepatitis
- chronic hepatitis
- pregnant women
- ribavirin
- foodborne infections
- waterborne infections
- immunocompromised patients
- zoonosis
